Literature DB >> 26268998

Urologic cancer in Japan: role of Japan at the frontier of issues in Asia.

Hideyuki Akaza1.   

Abstract

The characteristics of urological cancer in Japan can be summarized in the following points. (i) As the onset of this type of cancer is typically seen in elderly patients, it is becoming a major social issue in Japan that has already become an aging society. (ii) Many diverse treatment methods are available and a response is required that prioritizes quality of life. (iii) Although vigorous research and development efforts into new drugs are being carried out on a global level, resulting in beneficial medical agents becoming more readily available, unless concepts relating to cost vs. effectiveness are further developed and there is a real risk that medical systems and structures in their current form will become unsustainable. (iv) Although at the current point there are no original large-scale clinical trials being conducted in Asia, Japan has a wealth of experience of participating in many international joint clinical trials and it is therefore an urgent and pressing challenge to organize joint clinical trials in Asia and amass a body of knowledge that is unique to Asia. In view of this current situation and given Japan's position at the frontier of issues, it is important for Japan to take the initiative in Asia in cooperating with other Asian nations in efforts to resolve and overcome various challenges.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Japan; bladder cancer; kidney cancer; prostate cancer

Mesh:

Year:  2015        PMID: 26268998     DOI: 10.1093/jjco/hyv123

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

Review 1.  Prostate cancer trends in Asia.

Authors:  Hideyuki Akaza; Mizuki Onozawa; Shiro Hinotsu
Journal:  World J Urol       Date:  2016-09-19       Impact factor: 4.226

2.  Optimal body mass index cut-point for predicting recurrence-free survival in patients with non-muscle-invasive urothelial carcinoma of bladder.

Authors:  Satoru Yonekura; Fumihito Terauchi; Kenji Hoshi; Takehiko Yamaguchi; Shigeo Kawai
Journal:  Oncol Lett       Date:  2018-07-04       Impact factor: 2.967

3.  Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy.

Authors:  Omar Abdel-Rahman
Journal:  Ther Adv Urol       Date:  2017-11-08

4.  Evolution of the Histo-Epidemiological Profile of Urological Cancers in Togo

Authors:  Tchin Darré; Koué Folligan; Tchilabalo Matchonna Kpatcha; Kokou Kanassoua; Edoe Sewa; Sassil Daré; Kodjo Tengue; Koffi Amégbor; Gado Napo Koura
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

5.  Modified Glasgow prognostic score can predict survival of muscle invasive bladder cancer patients after radiotherapy.

Authors:  Koyo Kikuchi; Ryuji Nakamura; Takafumi Segawa; Hirobumi Oikawa; Hisanori Ariga
Journal:  J Radiat Res       Date:  2020-07-06       Impact factor: 2.724

6.  Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.

Authors:  Hiroyuki Nishiyama; Yoshiaki Yamamoto; Naoto Sassa; Kazuo Nishimura; Kiyohide Fujimoto; Satoshi Fukasawa; Minato Yokoyama; Hideki Enokida; Kenichi Takahashi; Yoshinobu Tanaka; Kentaro Imai; Takashi Shimamoto; Rodolfo Perini; Tara Frenkl; Dean Bajorin; Joaquim Bellmunt
Journal:  Int J Clin Oncol       Date:  2019-11-15       Impact factor: 3.402

7.  The relationship between urologic cancer outcomes and national Human Development Index: trend in recent years.

Authors:  Xiao-Fang Xia; Yi-Qiu Wang; Shi-Yi Shao; Xin-Yu Zhao; Shi-Geng Zhang; Zhong-Yi Li; Yi-Chu Yuan; Nan Zhang
Journal:  BMC Urol       Date:  2022-01-10       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.